Jenny Y. Chien
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Diabetes Treatment and Management, Diabetes Management and Research, Statistical Methods in Clinical Trials, Computational Drug Discovery Methods
Most-Cited Works
- → The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes(2013)870 cited
- → PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance(2011)198 cited
- → Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation(2005)175 cited
- → PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach(2011)170 cited
- → PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution(2011)133 cited
- → A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes(2011)118 cited
- → Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug(2013)101 cited
- → Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials(2015)97 cited
- → STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE(2006)74 cited
- → LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjects(2011)72 cited